《铂类抗肿瘤耐药机制研究进展》胡倩倩 王振辉等 药学进展2017年10期
 Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated.cancers. Nature 451, 1116–1120 (2008).
 Zhao, W., Wiese, C., Kwon, Y., Hromas, R. & Sung, P. The BRCA tumor suppressor network in chromosome damage repair by homologous recombination.Annu. Rev. Biochem. 88, 221–245 (2019).  Kuczynski, E. A., Sargent, D. J., Grothey, A. &Kerbel, R. S. Drug rechallenge and treatment beyond progression — implications for drug resistance.Nat. Rev. Clin. Oncol. 10, 571–587 (2013)
 Pajic, M. et al. Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clin. Cancer Res. 23, 7020–7033 (2017).
Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl Acad. Sci. USA 104, 12117–12122 (2007)
 Della Corte, C. M. et al. STING pathway expression identifies NSCLC with an immune-responsive. phenotype. J. Thorac. Oncol. 15, 777–791 (2020).
 Cancer Letters.Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer1 March 2021, Pages 163-171